Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?
Résumé
Comment on:
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. [EMBO Rep. 2018]
Inhibition of the receptor tyrosine kinase AXL, a key molecular driver of ovarian cancer, has recently been highlighted as promising therapeutic strategy. In this issue of EMBO Reports, Antony et al 1 have identified a novel mechanism of inhibition of AXL, wherein the GPI‐anchored tumour suppressor OPCML sequesters AXL into specialised plasma membrane domains where the phosphatase PTPRG is located, therefore facilitating AXL dephosphorylation. This [...]